No Data
No Data
GenScript Biotech Corporation (02367) will distribute a final dividend of HKD 0.44 per share on July 5.
Juzi Biotech (02367) announced that it will distribute a final dividend of HKD 0.4 per share on July 5, 2024.
GIANT BIOGENE: POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 13, 2024 AND PAYMENT OF FINAL DIVIDEND AND SPECIAL DIVIDEND
HK stocks surge | Giantson Bio (02367) rose more than 4%, with its sub-brand Corpumei 618 showing strong performance.
Juzi Biotech (02367) rose more than 4%, as of press time, up 4.23% to HKD 51.75, with a turnover of HKD 41.8058 million.
Giant Biogene Holding Co., Ltd. (HKG:2367) Boasts of Bullish Insider Sentiment With 58% Ownership and They Have Been Buying Lately
Key Insights Significant insider control over Giant Biogene Holding implies vested interests in company growth 58% of the company is held by a single shareholder (Daidi Fan) Insiders have been bu
Giant Biogene Places 33.2 Million Shares for About HK$1.63
Giant Biogene Holding (HKG:2367) successfully placed 33.2 million shares for about HK$1.63 billion to six placees, according to a Friday filing on the Hong Kong bourse. The average price for the Subsc
[Broker Focus] CMB International: China's pharmaceutical industry is expected to return to healthy growth and continues to be optimistic about leading innovative drugs and devices and high-growth medical consumer stocks
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has declined by 21.4%, significantly outperforming the MSCI China Index by 32.5%. The MSCI China Healthcare Index has only rebounded 9% since its low on April 19; currently, the dynamic price-earnings ratio of the industry index is 26.3 times, which is still below the 12-year historical average. It is expected that the medical equipment trade-in policy will soon be implemented. The policy is strong, wide-ranging, and has a long duration, which will effectively stimulate demand for medical devices. The bank looks forward to the introduction of a national policy to support innovative drugs and innovative devices. The bank expects that as industry-supporting policies fall one after another
No Data